These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15610929)

  • 21. Psychosocial conditions and the efficacy of clinically available anxiolytics.
    Haller J; Halász J; Majercsik E
    Curr Drug Targets; 2004 Oct; 5(7):655-64. PubMed ID: 15473255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation and treatment of anxiety symptoms and disorders in alcoholics.
    Kranzler HR
    J Clin Psychiatry; 1996; 57 Suppl 7():15-21; discussion 22-4. PubMed ID: 8690692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of self-report assessment in studies of anxiety disorders.
    Glass RM; Uhlenhuth EH; Kellner R
    J Clin Psychopharmacol; 1987 Aug; 7(4):215-21. PubMed ID: 2887588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perceived uncertainty, social support and psychological adjustment in older patients with cancer being treated with surgery.
    Lien CY; Lin HR; Kuo IT; Chen ML
    J Clin Nurs; 2009 Aug; 18(16):2311-9. PubMed ID: 19207802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of stressful life events which cause depression in the elderly, and the role of the social support network--a longitudinal study in Hokkaido prefecture].
    Kishi R; Urata Y; Saijo Y; Horikawa N; Sato T; Yoshioka E
    Seishin Shinkeigaku Zasshi; 2005; 107(4):369-77. PubMed ID: 15920947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of rating form for evaluating anxiolytics.
    Wang RI; Kochar C
    Psychopharmacol Bull; 1989; 25(2):291-5. PubMed ID: 2574898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
    Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of psychosocial adjustment in people with physical disease.
    Kocaman N; Kutlu Y; Ozkan M; Ozkan S
    J Clin Nurs; 2007 Mar; 16(3A):6-16. PubMed ID: 17518864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT-1A receptor responsiveness following subchronic administration of buspirone.
    Khan A; Haleem DJ
    Pak J Pharm Sci; 2006 Oct; 19(4):333-7. PubMed ID: 17105715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
    Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
    Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
    Schneider RB; Auinger P; Tarolli CG; Iourinets J; Gil-Díaz MC; Richard IH
    Parkinsonism Relat Disord; 2020 Dec; 81():69-74. PubMed ID: 33070009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of anxiolytic drugs on memory in anxious subjects.
    Lucki I; Rickels K
    Psychopharmacol Ser; 1988; 6():128-39. PubMed ID: 2905803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construct and discriminant validity and dimensionality of the Interview Schedule for Social Interaction (ISSI) in three psychiatric samples.
    Eklund M; Bengtsson-Tops A; Lindstedt H
    Nord J Psychiatry; 2007; 61(3):182-8. PubMed ID: 17523029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiolytic suppression of repetitive transcranial magnetic stimulation-induced anxiety in the rats.
    Isogawa K; Fujiki M; Akiyoshi J; Tsutsumi T; Kodama K; Matsushita H; Tanaka Y; Kobayashi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):664-8. PubMed ID: 15905012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of depression on quality of life of patients with type II diabetes mellitus.
    Eren I; Erdi O; Sahin M
    Depress Anxiety; 2008; 25(2):98-106. PubMed ID: 17311266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open trial of buspirone in the treatment of major depressive disorder.
    Schweizer EE; Amsterdam J; Rickels K; Kaplan M; Droba M
    Psychopharmacol Bull; 1986; 22(1):183-5. PubMed ID: 2873610
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
    Leveleki C; Sziray N; Levay G; Barsvári B; Soproni K; Mikics E; Haller J
    Brain Res Bull; 2006 Mar; 69(2):153-60. PubMed ID: 16533664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.